Appointment | December 01, 2021
Sygnature Discovery appoints Louisa Jordison as Chief Financial Officer
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
Featuring identity verification using artificial intelligence (AI), LabPort was designed to facilitate immediate results reporting for diagnostic testing even in high-volume, field-based testing environments
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Subscribe To Our Newsletter & Stay Updated
